Cetuximab-irdye800 (Various)

Other Medications

1 Clinical Trials

Description

Cetuximab-IRDye800 is a fluorescent imaging agent that combines the EGFR-targeting monoclonal antibody cetuximab with the near-infrared fluorescent dye IRDye800CW. This conjugate enables real-time visualization of EGFR-expressing colorectal cancer tissues during surgical procedures through fluorescence-guided imaging.

Mechanism of Action

The cetuximab component binds specifically to epidermal growth factor receptor (EGFR) proteins overexpressed on colorectal cancer cells. The attached IRDye800CW fluorophore emits near-infrared light when activated, allowing surgeons to identify tumor margins and residual cancer tissue with enhanced precision.

Side Effects

Infusion reactions Skin rash Fatigue Nausea Diarrhea Hypomagnesemia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04638036 Phase 1
Archived
Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery in Locally Advanced Rectal Cancer
Netherlands

Quick Info

Brand NameVarious
CategoryOther Medications
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.